Brightline-4 (1403.19): A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (MDM2-p53 antagonist) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma1,2
1. NCT06058793. https://classic.clinicaltrials.gov/ct2/show/NCT06058793. Accessed April 2024; 2. Santoro M, et al. AACR 2024. Poster CT288.